The Meihua Patent Portfolio spans 3,936 total patent families, with an active rate of 45.0% across granted and pending cases combined. Of these, 1,430 families stand granted, while 342 remain pending before patent offices worldwide. The grant rate stands at 36.3%, a figure drawn directly from prosecution outcomes recorded to date. Meanwhile, 2,164 families fall into lapsed, revoked, or expired status, reflecting cases that did not survive the maintenance cycle. These figures describe prosecution and maintenance activity only, not a verdict on patent quality or enforceability.
Filing activity peaked in 2020, when Meihua recorded 505 new families, the highest single-year count in the portfolio. China dominates jurisdictional coverage with a 96.9% share, and the company’s filings extend across 10 jurisdictions in total. On the technology side, class C12N (covering microorganism and enzyme related biotechnology) leads with 337 families, making it the single largest cluster in the portfolio.
This report is built to help readers interpret Meihua’s filing behaviour, not to pronounce judgment on specific inventions. Filing volume alone does not confirm commercial traction or a durable competitive edge in any given technology area. Readers evaluating licensing, litigation risk, or partnership opportunities should verify specific patent families independently before relying on them externally. What follows is a section by section walk through of portfolio health, filing trends, geographic spread, and technology concentration.
About Meihua
Company Profile: Meihua Group is a China based enterprise centred on synthetic biology and amino acid manufacturing. The company describes itself as a large high-tech private enterprise centered on synthetic biology technology and primarily focused on amino acids. Meihua Group was founded as a family business in northern China, and after more than 20 years of development has become a global leader in large scale bio-manufacturing and nutritional solutions.
It supplies the international market with customers from 150 different countries, employs over 13,000 people, and processes 6 million tons of corn annually with 3 million tons of amino acid production capacity. Its products serve animal nutrition, human nutrition, flavor enhancement, and healthcare sectors. Core product lines include amino acids, bio-based chemicals, DNA synthesis, pharmaceutical intermediates, functional food ingredients, and proteins or peptides. The company is listed on the Shanghai Stock Exchange, with its office in Langfang, Hebei Province.
In 2022, animal nutrition amino acids made up 53% of total revenue, growing 26.2%.
How Healthy is Meihua Patent Portfolio?
Patent portfolio health depends on how many families remain legally active versus how many have fallen away. Meihua’s legal status mix shows 36.3% granted, 8.7% pending, 46.1% lapsed, 5.8% revoked, and 3.1% expired. The composition chart in this section shows lapsed cases forming the single largest bucket, ahead of granted patents. This pattern is common in large Chinese portfolios where utility models carry shorter maintenance cycles and lower renewal costs. The active rate of 45.0% reflects granted plus pending families still alive within the system.
Patent type composition adds further texture to this picture. Utility models account for 54.5% of filings, patents make up 44.6%, and design filings are a marginal 0.9%. This heavy utility model tilt is typical for Chinese manufacturing and process heavy enterprises. Utility models offer faster examination and lower cost but shorter protection terms than invention patents. Taken together, the legal status and patent type data suggest a portfolio built for operational coverage. It prioritises speed and volume over long dated exclusivity in every single family filed.
How Has the Meihua Patent Portfolio Evolved Over Time?
Patent filing trends across Meihua’s history show a clear multi-phase build-up. Early filings were modest, with 58 in 2008 and figures staying under 100 annually through much of the following decade. Momentum picked up from 2016 onward, with 226 filings that year, followed by sustained growth. The filing-trend chart in this section highlights 2020 as the clear peak, with 505 new families recorded. Filings then eased to 397 in 2022 and 304 in 2023, suggesting a maturing rather than a collapsing filing programme.
The sharpest apparent change appears in the most recent years, with a -90.4% shift noted in the latest year comparison. This should not be read as a genuine filing collapse. Patent applications typically take 12 to 18 months to publish, so 2025 and 2026 figures are structurally incomplete. The 114 families logged for 2025 and 11 for 2026 will rise as records catch up. The underlying pattern through 2022 and 2023 points to a portfolio past its highest intensity period but still active.
Where Does the Meihua Patent Portfolio Prioritize Patent Protection?
Patent geography for Meihua is overwhelmingly domestic. China accounts for 96.9% of all filings, a concentration that dwarfs every other jurisdiction. The United States follows at 5.7%, with WIPO PCT filings at 4.7%, indicating some international routing intent. Japan, EP Patents, Taiwan, South Korea, Australia, Canada, and Singapore round out the remaining spread, each in low single digits. The geographic chart in this section makes this imbalance visually unmistakable.
This filing pattern aligns with Meihua’s manufacturing base and core customer geography centred on China. The comparatively thin presence in the United States, Japan, and Europe suggests selective rather than broad international filing. Companies in amino acid and bio-manufacturing sectors often reserve overseas filing for products with clear export relevance. Meihua’s pattern indicates a domestic-first protection strategy, with international filing reserved for specific markets. For competitors or partners assessing exposure, the risk of enforcement outside China currently looks limited based on filing volume alone.
Where is the Meihua Patent Portfolio Building Protection Across Key Technologies?
IPC analysis of the Meihua portfolio points squarely toward biotechnology and separation science. Class C12N, covering microorganisms and enzymes, leads with 337 families and an 18.2% share. Close behind sit C12R at 325 families (17.6%) and C12P at 295 families (16.0%), both tied to fermentation and biochemical production. The technology chart in this section shows these three classes clustering tightly at the top, well ahead of the rest.
Separation technology under B01D contributes 206 families, a 11.1% share, reflecting process engineering around purification. Pharmaceutical and healthcare related classes A61K and A61P add 184 and 156 families respectively. Together these clusters confirm Meihua’s patenting effort centres on fermentation biology, downstream separation, and health applications. This spread matches the company’s stated focus on amino acids, bio-based chemicals, and functional ingredients. Competitors watching the Meihua Patent Portfolio should treat these three core IPC clusters as the primary zone of technical contestability.
How Has the Meihua Patent Portfolio Evolved Across Filing Geographies?
Viewed year by year, China’s dominance in the Meihua portfolio only strengthens over time. Chinese filings rose from 115 in 2015 to 504 in 2020, mirroring the overall portfolio peak. The heatmap in this section shows every other jurisdiction filing in single or low double digits across the same years. United States filings touched 28 in 2021, their highest point in the matrix, then fell to single digits by 2023 and 2024.
WIPO PCT filings stayed fairly steady between 13 and 26 per year through 2022, then dropped sharply. Japan, EP Patents, Taiwan, South Korea, Australia, Canada, and Singapore all show thin, uneven filing across the decade. Several jurisdictions, including Taiwan and Canada, recorded zero filings in 2024. This pattern suggests that international filing follows specific product or project cycles rather than a steady annual programme. The data indicates China remains the consistent anchor, while overseas filing activity fluctuates with particular business needs.
Consultant’s Perspective on Meihua Patent Portfolio
Reading the Meihua Patent Portfolio as a whole, three things stand out to me. First, the scale is real: 3,936 families is a serious number for a bio-manufacturing enterprise. Second, the portfolio is built for domestic operational protection first, with 96.9% of filings in China. International filing exists but stays selective and inconsistent year to year. Third, the heavy lapsed share at 46.1% warrants attention, since it signals many families were not worth maintaining long term.
My read is that Meihua treats patenting as a working tool tied closely to production processes, not a pure IP monetisation play. The concentration in C12N, C12R, and C12P confirms fermentation and microbial technology as the company’s true technical core. For competitors, the message is clear: contest Meihua on process efficiency claims within these three classes specifically. For Meihua itself, broadening international filing in the United States and Europe could better match its stated 150-country customer base. Going forward, closer tracking of grant outcomes after 2023 filings will reveal whether recent applications convert at historical rates or face tighter scrutiny.
Explore Deeper Insights with Expertlancing Research
This overview only scratches the surface of what a detailed patent study can reveal. Expertlancing Research helps corporate strategy teams, IP counsel, and investors go deeper into family level validation, claim scope, and competitor benchmarking. Whether evaluating Meihua as a partner, competitor, or acquisition target, our analysts can build a tailored patent intelligence brief suited to your specific question. Reach out to ExpertLancing Research to commission a focused study beyond this summary view.